Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Spironolactone differently influences remodeling of the left ventricle and aorta in L-NAME-induced hypertension

F. Simko, J. Matúsková, I. Lupták, T. Pincíková, K. Krajcírovicová, S. Stvrtina, J. Pomsár, V. Pelouch, L. Paulis, O. Pechánová

. 2007 ; 56 (Suppl 2) : S25-S32.
. 2007 ; 56 (Suppl 2) : S25-S32.

Language English Country Czech Republic

Document type Journal Article, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc13034098

Aldosterone receptor antagonist, spironolactone, has been shown to prevent remodeling of the heart in several models of left ventricular hypertrophy. The aim of the present study was to determine whether the treatment with spironolactone can prevent hypertension, reduction of tissue nitric oxide synthase activity and left ventricular (LV) and aortic remodeling in N(G)-nitro-L-arginine methyl ester (L-NAME)-induced hypertension. Four groups of rats were investigated: control, spironolactone (200 mg/kg), L-NAME (40 mg/kg) and L-NAME + spironolactone (in corresponding dosage). Animals were studied after 5 weeks of treatment. The decrease of NO-synthase activity in the LV and kidney was associated with the development of hypertension and LV hypertrophy, with increased DNA concentration in the LV, and remodeling of the aorta in the L-NAME group. Spironolactone prevented the inhibition of NO-synthase activity in the LV and kidney and partially attenuated hypertension and LVH development and the increase in DNA concentration. However, remodeling of the aorta was not prevented by spironolactone treatment. We conclude that the aldosterone receptor antagonist spironolactone improved nitric oxide production and partially prevented hypertension and LVH development without preventing hypertrophy of the aorta in NO-deficient hypertension. The reactive growth of the heart and aorta seems to be controlled by different mechanisms in L-NAME-induced hypertension.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc13034098
003      
CZ-PrNML
005      
20151006115928.0
007      
ta
008      
131021s2007 xr d f 000 0|eng||
009      
AR
024    __
$a 10.33549/physiolres.931394 $2 doi
035    __
$a (PubMed)17824810
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xr
100    1_
$a Šimko, Fedor $u Department of Pathophysiology and Third Clinic of Medicine, Comenius University, Bratislava, Slovak Republic. fedor.simko@fmed.uniba.sk $7 xx0097039
245    10
$a Spironolactone differently influences remodeling of the left ventricle and aorta in L-NAME-induced hypertension / $c F. Simko, J. Matúsková, I. Lupták, T. Pincíková, K. Krajcírovicová, S. Stvrtina, J. Pomsár, V. Pelouch, L. Paulis, O. Pechánová
520    9_
$a Aldosterone receptor antagonist, spironolactone, has been shown to prevent remodeling of the heart in several models of left ventricular hypertrophy. The aim of the present study was to determine whether the treatment with spironolactone can prevent hypertension, reduction of tissue nitric oxide synthase activity and left ventricular (LV) and aortic remodeling in N(G)-nitro-L-arginine methyl ester (L-NAME)-induced hypertension. Four groups of rats were investigated: control, spironolactone (200 mg/kg), L-NAME (40 mg/kg) and L-NAME + spironolactone (in corresponding dosage). Animals were studied after 5 weeks of treatment. The decrease of NO-synthase activity in the LV and kidney was associated with the development of hypertension and LV hypertrophy, with increased DNA concentration in the LV, and remodeling of the aorta in the L-NAME group. Spironolactone prevented the inhibition of NO-synthase activity in the LV and kidney and partially attenuated hypertension and LVH development and the increase in DNA concentration. However, remodeling of the aorta was not prevented by spironolactone treatment. We conclude that the aldosterone receptor antagonist spironolactone improved nitric oxide production and partially prevented hypertension and LVH development without preventing hypertrophy of the aorta in NO-deficient hypertension. The reactive growth of the heart and aorta seems to be controlled by different mechanisms in L-NAME-induced hypertension.
650    _2
$a zvířata $7 D000818
650    _2
$a antihypertenziva $x farmakologie $x terapeutické užití $7 D000959
650    _2
$a aorta $x účinky léků $x patologie $x patofyziologie $7 D001011
650    _2
$a krevní tlak $x účinky léků $7 D001794
650    _2
$a proliferace buněk $x účinky léků $7 D049109
650    _2
$a replikace DNA $x účinky léků $7 D004261
650    _2
$a srdeční komory $x účinky léků $x enzymologie $7 D006352
650    _2
$a hypertenze $x chemicky indukované $x komplikace $x farmakoterapie $x metabolismus $x patologie $x patofyziologie $7 D006973
650    _2
$a hypertrofie levé komory srdeční $x farmakoterapie $x etiologie $x metabolismus $x patologie $x patofyziologie $7 D017379
650    _2
$a ledviny $x účinky léků $x enzymologie $7 D007668
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a antagonisté mineralokortikoidních receptorů $x farmakologie $x terapeutické užití $7 D000451
650    _2
$a NG-nitroargininmethylester $7 D019331
650    _2
$a oxid dusnatý $x metabolismus $7 D009569
650    _2
$a synthasa oxidu dusnatého $x antagonisté a inhibitory $x metabolismus $7 D019001
650    _2
$a krysa rodu Rattus $7 D051381
650    _2
$a potkani Wistar $7 D017208
650    _2
$a spironolakton $x farmakologie $x terapeutické užití $7 D013148
650    _2
$a časové faktory $7 D013997
650    _2
$a remodelace komor $x účinky léků $7 D020257
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Matúšková, J. $u Department of Pathophysiology, Comenius University, Bratislava, Slovak Republic $7 _AN075350
700    1_
$a Ľupták, Ivan $u Department of Pathophysiology, Comenius University, Bratislava, Slovak Republic $7 xx0078706
700    1_
$a Pinčíková, Terézia $u Department of Pathophysiology, Comenius University, Bratislava, Slovak Republic $7 xx0101984
700    1_
$a Krajčírovičová, Kristína $u Department of Pathophysiology, Comenius University, Bratislava, Slovak Republic $7 xx0104738
700    1_
$a Štvrtina, Svetoslav $u Institute of Pathology, School of Medicine, Comenius University, Bratislava, Slovak Republic $7 xx0102705
700    1_
$a Pomšár, J. $u Department of Pathophysiology, Comenius University, Bratislava, Slovak Republic $7 _AN075353
700    1_
$a Pelouch, Václav, $u Department of Medical Chemistry and Biochemistry, Second Faculty of Medicine, Charles University and Center for Cardiovascular Research, Prague, Czech Republic $d 1941-2010 $7 nlk20010095562
700    1_
$a Paulis, Ľudovít $u Department of Pathophysiology, Comenius University, Bratislava, Slovak Republic; Institute of Normal and Pathological Physiology, Slovak Academy of Sciences, Bratislava, Slovak Republic $7 xx0093004
700    1_
$a Pecháňová, Oľga, $u Institute of Normal and Pathological Physiology, Slovak Academy of Sciences, Bratislava, Slovak Republic; Institute of Physiology, Academy of Sciences of the Czech Republic, Prague, Czech Republic $d 1962- $7 xx0075055
773    0_
$w MED00003824 $t Physiological research $x 0862-8408 $g Roč. 56,Suppl 2 (2007), s. S25-S32
773    0_
$t The importance of nitric oxide in the hemodynamically overloaded circulation $x 0862-8408 $g Roč. 56,Suppl 2 (2007), s. S25-S32 $w MED00163484
856    41
$u http://www.biomed.cas.cz/physiolres/pdf/56%20Suppl%202/56_S25.pdf $y plný text volně přístupný
910    __
$a ABA008 $b A 4120 $c 266 $y 4 $z 0
990    __
$a 20131021 $b ABA008
991    __
$a 20151006120113 $b ABA008
999    __
$a ok $b bmc $g 999456 $s 832568
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2007 $b 56 $c Suppl 2 $d S25-S32 $i 0862-8408 $m Physiological research $n Physiol. Res. (Print) $x MED00003824
BMC    __
$a 2007 $b 56 $c Suppl 2 $d S25-S32 $i 0862-8408 $m The importance of nitric oxide in the hemodynamically overloaded circulation $n $x MED00163484
LZP    __
$b NLK138 $a Pubmed-20131021
Back

Find record

Citation metrics

Archiving options